Update in Cardiology
Authors: Robert O. Bonow
Journal: Annals of Internal Medicine (2004)

Updates19 October 2004Update in CardiologyRobert O. Bonow, MDRobert O. Bonow, MDFrom Northwestern University Feinberg School of Medicine, Chicago, Illinois.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-141-8-200410190-00010 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This year's Update in Cardiology incorporates the most interesting, innovative, and important articles in the field from 2003, including papers on risk factors for heart disease, new treatment approaches, and issues in chronic heart failure. Despite strides in public education and treatment, cardiovascular disease is still the leading cause of death in the United States. Since 1997, the relative mortality rates from coronary artery disease and stroke have decreased by 4.5% and 1.6%, respectively, and the prevalence of hypercholesterolemia and of smoking has decreased by 14% and 3.8%, respectively. However, in that same period, the national prevalence of hypertension, physical ...References1. Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, et al . Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med. 2002;347:716-25. [PMID: 12213942] CrossrefMedlineGoogle Scholar2. Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-7. [PMID: 10880413] CrossrefMedlineGoogle Scholar3. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation. 2003;108:161-5. [PMID: 12835213] CrossrefMedlineGoogle Scholar4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. [PMID: 10639539] CrossrefMedlineGoogle Scholar5. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. [PMID: 10471456] CrossrefMedlineGoogle Scholar6. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7. [PMID: 10376614] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Northwestern University Feinberg School of Medicine, Chicago, Illinois.Disclosures: None disclosed.Corresponding Author: Robert O. Bonow, MD, Division of Cardiology, Northwestern University Feinberg School of Medicine, 201 East Huron Street, Suite 10-240, Chicago, IL 60611. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 October 2004Volume 141, Issue 8Page: 628-634KeywordsACE inhibitorsBlood pressureC-reactive proteinsCholesterolCongenital heart diseaseHazard ratioHeart failureMedical risk factorsMetabolic syndromeMortality ePublished: 19 October 2004 Issue Published: 19 October 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...